Complexity of Sarcomere Protein Gene Mutations in Restrictive Cardiomyopathy by Wang, Shuai & Peng, Daoquan
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books






Complexity of Sarcomere Protein Gene Mutations
in Restrictive Cardiomyopathy
Shuai Wang and Daoquan Peng
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/66378
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons 
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, 
and reproduction in any medium, provided the original work is properly cited. 
in Restrictive Cardi yopathy
Shuai Wang and Daoquan Peng
Additional information is available at the end of the chapter
Abstract
Restrictive cardiomyopathy (RCM) is characterized by impaired filling of the ventricles 
in the presence of normal wall thickness and systolic function. Although idiopathic RCM 
is rare compared to other types of cardiomyopathy, the effects are severe. Until recently, 
many sarcomere genes previously described to be causative mutations in hypertrophic 
cardiomyopathy and dilated cardiomyopathy have been reported in RCM. Nowadays, it 
is accepted that primary RCM is also within the spectrum of sarcomere disease. However, 
the relationship between the identified mutations in sarcomere genes and clinical mani‐
festation are complex, and the possible pathogenic mechanisms are not fully understood. 
Besides, many RCM‐related sarcomere mutations were reported to cause variable clinical 
phenotype. Occasionally, “phenotype transition” may also be seen in an individual who 
was previously diagnosed with RCM.
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1. Introduction
Restrictive cardiomyopathy (RCM) is characterized by impaired filling of the ventricles in the 
presence of normal wall thickness and systolic function. While RCM is rare compared to other 
primary cardiomyopathies, most affected individuals have severe signs and symptoms of 
heart failure and majority die shortly after diagnosis unless they receive a cardiac transplant 
[1]. According to the etiology, RCM has been classified as primary or secondary. Secondary 
RCM refers to the conditions in association with local inflammation (Loeffler cardiomy‐
opathy, endomyocardial fibrosis, and eosinophilic endomyocardial disease) or infiltrative 
 (amyloidosis and sarcoidosis) or storage disease (hemochromatosis, glycogen storage disease, 
and Fabry disease, etc.) [2]. Primary RCM includes RCM ascribed to inherited or sporadically 
acquired mutations or in many cases due to unknown etiology. So far, through mutation 
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screening of different individuals and families presenting the RCM phenotype, mutations 
in multiple sarcomere genes have been identified to be linked with RCM, which has greatly 
expanded our understanding about “idiopathic RCM.” However, the relationship between 
the identified sarcomeric mutations and clinical manifestation are complex and many puzzles 
still exist. The mechanism behind the genotype‐phenotype correlation is not clearly under‐
stood. Most of these RCM‐associated sarcomeric mutations, when mutated at specific sites, 
are also known to induce HCM or DCM. Even people carrying the same mutation of the same 
sarcomeric gene may exhibit heterogenetic manifestations. “Phenotype transition” may even 
been seen at a late stage of RCM resulting in atypical RCM.
2. Multiple sarcomeric gene mutations in human RCM
The sarcomere contains different protein involved in muscle contraction. Two major components 
are actin, which constitutes the backbone of the thin filament, and myosin, which makes up the 
thick filament. The interaction of myosin and actin causing the sliding of the thin filaments along 
the thick filaments results in muscle contraction and force development. Association and disas‐
sociation of myosin and actin are regulated in a Ca2+‐dependent manner by the troponin‐alphat‐
ropomysin (Tm) complex. The actin‐myosin contractile apparatus, which consists of five thin 
filament proteins (actin, tropomyosin, and troponin T, I, and C) and three thick filament proteins 
(myosin heavy chain, essential light chain, and regulatory light chain), plays a key role in regu‐
lating the sarcomere function. So far, except for troponin C, mutations in the other thin filament 
and thick filament proteins have all been identified in RCM. Besides, a series of mutations in 
other regulatory sarcomere proteins such as myosin‐binding protein C, titin, and Z‐disc proteins 
also have been recognized to induce diastolic dysfunction resulting in a restrictive phenotype.
2.1. Cardiac troponin mutation
Cardiac troponin is located at regular intervals along the thin filament and consists of three sub‐
units: cardiac troponin C (cTnC), troponin I (cTnI), and troponin T (cTnT). cTnC acts as a Ca2+ 
sensor, which confers Ca2+ sensitivity to muscle contraction [3]. Cardiac TnI is the inhibitory 
subunit, primarily functioning to prevent actin and myosin from interacting in the absence of 
Ca2+. The cTnT subunit binds to tropomyosin (Tm) and is responsible for transmitting the Ca2+‐
binding signal from cTn to Tm [4]. Electrical depolarization of the cell membrane opens the 
L‐type calcium channels and allows Ca2+ influx, which incites release of Ca2+ from sarcoplasmic 
reticulum due to opening of the ryanodine receptors. The released Ca2+ binds to cardiac tropo‐
nin C and induces conformational changes in the troponin T‐tropomyosin complex, resulting 
in displacement of cTnI from actin and subsequent association of actin with myosin. Currently, 
nine mutations in genes encoding cTnI and three dominant mutations in genes encoding cTnT 
have been reported in human RCM and no mutations have been  identified in cTnC yet.
2.1.1. Troponin I mutation
The gene of cardiac TnI (TNNI3) is situated on the 19th chromosome (19q13.4) and consists of 
eight exons and seven introns. The mature molecule of cTnI is 209 a.a long and consists of five 
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domains: (1) N‐terminal domains, (2) IT‐arm, (3) inhibitory domain, (4) regulatory domain, 
and (5) C‐terminal mobile domains [5]. Until now, RCM‐related cTnI mutations are found 
located in the inhibitory domain and the C‐terminal domain.
2.1.1.1. Missense mutations located at the inhibitory domain
The inhibitory domain of hcTnI spans residues 137–148 [6, 7], some also reported a differ‐
ent border of this region (residues 129–148) [6, 8]. In the absence of Ca2+, residues 138–148 of 
the inhibitory domain interact with actin [9] and shift the tropomyosin molecule, impeding 
the antomyosin‐complex formation [10]. Two of the RCM mutations are localized within this 
important region. The first one is 797T→A nucleotide substitution of exon 7, which led to a 
Leu144Gln (L144Q) amino acid substitution [11]. The second mutation is 799C→T nucleotide 
substitution of exon 7 that leads to an Arg145Trp (R145W) amino acid substitution [11].
Data from in vitro experiment showed that both L144Q and R145W alter myofilament sen‐
sitivity to Ca2+. Skinned cardiac fiber experiment, which measures the Ca2+‐buffering capac‐
ity of the myofilament while measuring the development of tension and maximal force, 
revealed that these two mutations resulted in increase of Ca2+ sensitivity of force development 
in skinned fibers from transgenic mice. In addition, a significant increase in the basal force 
was shown compared to WT cardiac fiber [12]. Measurement of myofilament ATPase activ‐
ity revealed that L144Q and R145W mutant showed an increase in the basal ATPase at low 
Ca2+ concentrations. Besides, fibers from these two mutants exhibited markedly increased Ca2+ 
sensitivity of ATPase activity [13].
2.1.1.2. Missense mutations located at the mobile C-terminal domain
The mobile C‐terminal domain of hcTnI is further divided into the H4 α‐helix (residues 164–
188) and the C‐terminal part (residues 199–210) [5]. 865G→A nucleotide substitution of exon 
7 that led to an Ala171Thr amino acid substitution and an 886A→G nucleotide substitution of 
exon 7, which resulted in a Lys178Glu (K178E) amino acid substitution both occurred within 
the H4 α‐helix region and have been identified in RCM patients. Since these two mutations 
are known to be located within the actin‐binding sites (residues 173–181) [14, 15], K178E and 
Ala171Thr mutations may influence the inhibitory function through actin binding.
Although the structure of the C‐terminal part of hcTnI which consists of residues 190–210 
is not fully understood, it is critical for a full inhibitory activity and Ca2+ sensitivity of force 
development because it binds to actin and helps to maintain the thin filament in a blocked 
state [16]. Mutations occurred at the C‐terminal domain may destabilize or decrease its inter‐
actions with actin in the absence of Ca2+, consequently relieving cTnI inhibition [17]. Up to 
now, RCM‐related mutant Asp190His (D190H), Arg192His (R192H), and Arg204His (R204H) 
have been localized within the conserved C‐terminal region of the protein [11, 18]. In vitro 
experiments revealed that two of these mutants D190H and R192H markedly increased the 
filament sensitivity to Ca2+, while another mutation R204H has been reported to result in a dis‐
ruption of the normal interaction between cTnI‐cTnC and cTnI‐cTnT. It remains to be further 
determined what conformational changes happened in these mutant that lead to disrupted 
interaction between cTnI‐actin and cTnI‐cTnC.
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2.1.1.3. Two deletion mutations
Deletion of nucleotides usually causes frame shift and the introduction of a premature stop 
codon. Two deletion mutations of TNNI3 which impaired relaxation of myocardium and 
resulted in a restrictive filling pattern were reported to be located in exon 7 and cause trun‐
cation of C‐terminal portion of cTnI. The truncated cTnI which lost its C‐terminal portion is 
susceptible to degradation and has reduced inhibitory capacity on the thin filament since 
C‐terminal contains the second binding domain for actin and cTnC [19, 20].
2.1.2. Troponin T mutation
cTnT anchors the troponin complex to Tm and plays a critical role in modulating ATPase 
activation when Ca2+ concentrations achieve threshold levels. Until now, three different muta‐
tions in the cTnT gene (TNNT2) linked to RCM have been identified. However, the molecular 
pathogenesis of these cTnT mutations is not clear [20–22].
3. α‐Cardiac actin (ACTC)
Actin is a major constituent of the thin filament and spans the length of thin filament. 
Together with myosin, actin generates force and transmits this force from the sarcomere to 
the surrounding syncytium via the thin filament [23]. RCM mutations in the ACTC gene are 
extremely rare and only one ACTC mutation has been reported in RCM (nucleotide substitu‐
tion in exon 5 g. 4642G→C which lead to an Asp313His amino acid substitution). However, 
the significance of this variant is uncertain.
4. α‐Tropomyosin (TPM1)
In cardiac muscles, tropomyosin together with troponin forms the principal mechanism by 
which contractility is regulated in response to the Ca2+ concentration. In the absence of Ca2+, 
tropomyosin prevents productive myosin head binding. In systole, tropomyosin moves in 
response to Ca2+ binding to allow partial myosin attachment, which resulted in further shift 
of tropomyosin to expose fully the interaction site on actin [24]. Recently, a novel missense 
mutation in α‐tropomyosin, c.835A>C p.Asn279His has been identified in a patient with pri‐
mary RCM [25]. However, the significance of this variant is not clear since family evaluation 
did not show cosegregation.
5. β‐Myosin heavy chain (MYH7)
Myosin is a dimeric protein consisting of two heavy chains and two associated pairs of light 
chains. The ~23‐kb long human MYH7 gene, located on chromosome 14, contains 40 exons 
that direct the synthesis of the 1935 amino acid β‐myosin heavy chain [26]. Although over 
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500 disease‐causing point mutations have been found in human MYH7 gene, most of them 
are reported in HCM, only four of these variants are identified in patients with primary 
RCM [27–32]. The understanding about the genotype‐phenotype correlation between the 
reported MYH7 mutation and RCM are very limited. MYH7 contains different functional 
domains, including the globular head domain (S1), the neck or hinge region (S2), and the 
tail (light meromyosin) [33, 34]. Although many mutations have been identified to cluster 
in functional hotspots due to the development of high throughput sequencing, all the above 
mentioned RCM‐related MYH7 mutations located at regions where no definite function has 
been assigned to so far [28]. Besides, whether haploinsufficiency may contribute to the conse‐
quence of the variants is not clear.
6. Ventricular myosin essential light chain (MYL3) and ventricular 
myosin regulatory light chain (MYL2)
Myosin assembles into hexamers comprising two heavy chains and two pairs of each light 
chain isoform. The light chain forms a stabilizing collar around the α‐helical neck of the heavy 
chain, a region of the myosin multimer thought to function as the level arm. Mutation in the 
gene encoding the essential light chain of myosin (MYL3 Met149Val) and the regulatory light 
chain of myosin (MYL2 Glu22Lys) was previously reported to correlate with marked diastolic 
dysfunction and restrictive physiology both in human and transgenic mice [35]. Interestingly, 
carriers with simultaneous mutation in both MYL3 and MYL2 showed different phenotypes. 
While patients with heterozygous mutation in MYL2 (p.Gly57Glu) and homozygous muta‐
tion in MYL3 (p.Glu143Lys) had severe, early onset RCM, double heterozygote for these vari‐
ants have no evidence of cardiomyopathy [25, 36]. It is speculated that Glu143Lys substitution 
may be responsible for this heterogeneity through a loss of function mechanism. This specula‐
tion is based on (1) carriers with one mutant allele were clinically silent [36], while homozy‐
gotes for the mutation have severe, early‐onset cardiomyopathy [25]. If the cardiomyopathy 
was caused by a dominant‐negative mechanism, an intermediate phenotype in heterozygotes 
would be expected. (2) The substitution occurs in a surface‐exposed loop of the essential light 
chain [37], which makes it less likely to disrupt protein conformation or stability. The site‐
directed mutagenesis of the corresponding loop domain was confirmed to have no effect on 
binding between light and heavy chains [38]. Further study using transgenic animal models 
may help to answer this question.
7. Myosin‐binding protein C (MYBPC3)
Cardiac myosin‐binding protein C is a modular polypeptide located at the C‐zone in the stri‐
ated muscles and binds myosin heavy chain in thick filament and titin in elastic filaments [39]. 
More than 150 mutations identified in MYBPC3 have been reported, which is the most com‐
mon genetic cause of HCM [40, 41]. Recently, variants of MYBPC3 have also been reported to 
be RCM‐causing mutation [42, 43].




The giant protein titin acts as the third filament system of the sarcomere, in addition to the 
actin and myosin filament. It physically connects myosin fibers to actin polymers and is 
attached to the Z‐line. Titin consists of four structurally and functionally distinct regions. 
(1) The N‐terminal titin binds to various Z‐disk proteins and acts as an anchor, which is 
composed of Z‐repeats and multiple immunoglobulin (Ig) domains. (2) Elastic I‐band region 
contains the important PEVK portion (proline, glutamate, valine, and lysine) and acts as 
the molecular spring. (3) Stabilizing A‐band region binds to the thick muscle filaments and 
contains Ig‐like, fibronectin type III (fibronection3) domain. (4) M‐band region contains the 
unique serine‐threonine kinase domain modulating titin expression and turnover, with C‐
terminus of titin embedding in the M‐line [44–46]. When the sarcomere is stretched during 
diastole, the I‐band segments gradually lengthen and develop passive tension and therefore, 
titin is a major determinant of the stiffness of myocardium [47].
Currently, two mechanisms are known to modulate titin's passive stiffness. (1) Titin‐based 
passive tension is critically defined by the ratio of the two major adult cardiac isoforms (N2BA 
and N2B). As a general rule, longer titin isoforms with longer PEVK repeats in the I‐band have 
more elasticity, whereas shorter isoforms provide more passive stiffness [48]. In adult cardiac 
muscle, two major isoforms are present: the long compliant N2BA and the shorter stiff N2B. 
In healthy adult, the ratio of N2BA to N2B in human left ventricle is 40:60 [49]. Moreover, the 
right ventricle expresses more N2BA than does the left ventricle [50]. In conditions with con‐
centric remodeling such as hypertension or aortic stenosis with diastolic function, a decreased 
N2BA:N2B ratio was shown [51, 52]. (2) Another more short‐term mechanism modulating 
titin's passive stiffness is caused by post‐translational modification influencing phosphoryla‐
tion states. Titin could be phosphorylated at the PEVK domain and the cardiac‐specific N2B 
domain, and phosphorylated titin exhibited decreased titin‐based passive tension [53].
Titin, known to be the major disease‐causing gene for DCM, is encoded by a single gene 
TTN on chromosome 2q31 [54]. Interestingly, recent clinical and genetic studies have estab‐
lished the role of titin defects in the pathophysiology of diastolic dysfunction and RCM. A de 
novo missense mutation of Titin c.22862A > G replacing adenine by guanine at position 109 
of exon 226, resulting in the substitution of an evolutionally conserved tyrosine by cysteine 
(p.Y7621C) has been reported to result in early‐onset family RCM with severe heart failure 
[55]. Structural analysis revealed that p.Y7621C mutation is likely to disrupt the hydrophobic 
core within fibronectin3 domain, which locates in the A/I junction region [55]. However, how 
this TTN mutation might affect cardiac function and lead to the consecutive development of 
RCM is unknown.
9. Myopalladin (MYPN)
Myopalladin (MYPN) is an Ig‐domain family member protein that has been reported to be a 
key intermediate molecule at the Z‐disc involved in sarcomere/Z‐disc assembly and  regulation 
of gene expression in cardiac cells [56]. Through genetic screening for MYPN mutations in 
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large cohorts of patients with cardiomyopathy, 15 MYPN variants were identified, of which 
a nonsense mutation (p.Q529X) was identified in an RCM family with variable penetrance 
[57]. Q529X was found to disturb different functional domains of MYNP. MYNP contains 
five Ig domains (two N‐terminal and three C‐terminal). Central and C‐terminal domains of 
MYPN bind at the Z‐disc to α‐actinin and nebulette (NEBL), respectively. This actinin‐MYPN‐
NEBL complex tethers actin and titin to the Z‐disc and may play roles in the signaling and 
regulation of gene expression in response to muscle stress. The N‐terminal domain of MYNP 
binds cardiac ankyrin repeat protein (CARP), which is involved in the control of muscle gene 
expression [58]. Q529X mutation truncates the C‐terminus of MYNP, including the NEBL‐ 
and α‐actinin‐binding domains. Comparative immunohistochemistry of human heart tissue 
was performed on specimens from the siblings with RCM and from normal control subjects 
without MYPN mutation as well as in neonatal rat cardiomyocytes (NRCs) expressing green 
fluorescent protein (GFP) chimeras of WT‐ and Q529X‐MYPN. Disrupted sarcomeric Z‐discs 
with abnormally diffuse MYPN codistributed focally with abnormal sarcomeric α‐actin, 
localization were seen in the specimen from siblings with RCM and NRCs expressing Q529X‐
MYPN [57]. Therefore, losing the NEBL and α‐actinin‐binding domain results in severe dis‐
turbance of sarcomere/Z‐disc assembly, which may have impact on early myofibrillogenesis 
and resulted in RCM. Besides, since MYPN localizes both at sarcoplasm and nucleus, mutant 
MPPN‐Q529X protein in the nucleus was reported to result in downregulation of CARP 
expression and upregulation of MLP and desmin, augmenting fibrotic restrictive remodel‐
ing [59]. In addition, truncated proteins are usually unstable due to decay of mRNA and/or 
protein degradation through the lysosome or ubiquitin‐proteasome system. Although MYPN 
mRNA was not affected by the Q529X‐MYPN mutation in the myocardium, mutant MYPN 
was relatively unstable compared with WT protein [57]. Therefore, insufficient quantities of 
the protein (haploinsufficiency) may be partly involved in dysfunction of the protein.
10. Mutations cause variable phenotypes
The molecular mechanisms by which gene mutation cause cardiomyopathy can usually be 
explained by two alternative ways. One is mutation may cause structural and functional 
change in the protein, which should be analyzed in four different levels: (1) change in the 
deoxyribonucleic acid sequence, (2) the actual amino acid change, (3) the changes in Ca2+ 
sensitivity of force development and ATPase activity, and (4) the change in protein‐protein 
interaction. The other mechanism may involve insufficient quantities of the protein due to 
instability of the mutant protein leading to haploinsufficiency [23].
However, it is now evident that different mutations in one gene could cause multiple phe‐
notypes. It is also intriguing that even for a given single mutation and even within a sin‐
gle family disparate phenotypes can be seen. For example, the cTnT lle79Asn mutation has 
been shown to be associated with HCM, DCM, and RCM within a single pedigree [60]. This 
implies that factors just beyond the pathogenic sarcomere mutation influence the phenotype. 
Therefore, the model of sarcomeric cardiomyopathy as monogenic disease following simple 
Mendelian pattern of inheritance is an oversimplification. Theoretically, a discrete number of 
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reasons can account for phenotypic diversity. (1) First of all, patients may carry more than one 
disease‐associated mutations, which is underestimated in most cases. Recent genotyping sug‐
gests that multiple cardiomyopathy patients have more than one mutation in the same gene 
or mutations in different genes. For example, in a study carried out in 292 HCM patients, 13 
were found to carry at least 2 mutations [61, 62]. However, the number of patients carrying 
at least two mutations is likely to be significantly underestimated since many genetic studies 
typically investigate less than 15 genes for mutations associated with cardiomyopathy [63]. 
(2) Secondly, different expression and the incorporation rate of the mutant sarcomeric pro‐
teins in the heart may also contribute to the heterogeneity of the disease. A few examples in 
HCM have been published. Heterozygous individuals carrying the βMHC Lys207Gln muta‐
tion developed an HCM phenotype, but a homozygous individual developed a DCM‐like 
phenotype [61]. In another case, homozygous carriers of cTnT Ser179Phe mutation exhibited 
profound left and right ventricular hypertrophy [64] while heterozygous carriers had little or 
no hypertrophy [65]. (3) Third, mutant proteins are usually unstable due to decay of mRNA 
and/or degradation through the lysosome or ubiquitin‐proteasome system, especially in the 
case of nonsense mutation [66]. Because of genetic polymorphisms, individuals with RCM 
are likely to have substantial difference in their genome sequence including disease‐modifier 
genes which are involved in post‐translational or translational regulation, resulting in dif‐
ferent amounts of mutant protein. This mechanism may interfere with the development of 
the phenotype and explain different penetrance of a specific mutation. (4) Lastly, sarcomere 
gene mutation induces serials of maladaptive features, ranging from the prolongation of car‐
diomyocyte action potential to microvascular dysfunction, from intracellular calcium abnor‐
mality to dysregulation of collagen turn‐over, and from energetic derangement to abnormal 
sympathetic activation [67]. The extent and the rate at which each of these features occur 
and evolve are quite variable within individual patients. Therefore, the clinical heterogeneity 
of a specific sarcomere gene mutation may partly be ascribed to different stages of disease 
progression [68]. Although epigenetics and environmental factors are likely to be relevant 
in sarcomeric cardiomyopathies, there have been no studies yet describing how epigenetic 
modification and environmental factors may affect phenotype in sarcomeric RCM.
11. Phenotype transition
Occasionally, with the progression of disease, “phenotype transition” may be seen in a given 
individual who was initially diagnosed with a specific type of cardiomyopathy. This situation 
could often be seen in patients who was initially diagnosed with HCM and gradually devel‐
oped into end‐stage of the disease. The morpho‐functional manifestation in this advanced 
stage usually exhibits two extremes: hypokinetic‐dilated from or hypokinetic‐restrictive form 
which could be hard to distinguish from primary DCM and RCM [68]. The “HCM to RCM” 
transition has been discussed above. There is another situation that patients initially diag‐
nosed with primary RCM could undergo persistent cardiac remodeling resulting atypical 
phenotype at a later stage of the disease. Although the main impairment of RCM is diastolic 
dysfunction, deterioration of systolic function has been observed in some patients. In a ret‐
rospective study, it was reported that 16% of 94 primary RCM patients was observed to have 
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systolic dysfunction [69]. Another study carried out in pediatric RCM reveals that although 
all the 18 children had preserved ventricular systolic function at diagnosis, 6 of them later 
presented a deteriorated ventricular systolic function and eventually required inotropic sup‐
port [70]. In the RCM model using transgenic mice noticeable impaired systolic was observed 
over a time of 10 months. By the time, those RCM mice presented with signs of severely 
aggravated congestive heart failure and some of them died [71]. This disease progression is 
consistent with some of the clinical observation, suggesting that systolic dysfunction may be 
responsible for the end‐stage lethal heart failure. As for the mechanism, some proposed that 
ischemia may be a bridge between the progression of diastolic dysfunction and the develop‐
ment of systolic function, based on evidence of ischemia observed in hearts for autopsy from 
RCM patients and transgenic RCM mice [71–73]. Besides, it is presumed that reduced capil‐
lary density due to interstitial fibrosis and increased extravascular compressive force in the 
restrictive heart may also induce ischemia [74]. Of note, although an RCM patient may appear 
to have systolic dysfunction and low cardiac output, enlargement of ventricle is seldom seen, 
probably because the molecular mechanism and sarcomeric mechanics of RCM and DCM are 
opposite [75].
12. Summary
In the past decades, clinical and genetic studies suggest that primary RCM is part of a spec‐
trum of sarcomeric disease. Since RCM is associated with severe prognosis, ongoing and 
future basic science will continue to dissect the precise pathways driving how these muta‐
tions remodel the heart, and identify rational therapies targeting pathophysiological aspects 
to interrupt the emergency of pathology. On the other hand, it is also important to realize that 
genes contain information that is essential for the development of the phenotype but not neces‐
sarily complete. The final phenotype is determined not only by the causal mutation but also by 
the modifier genes, each exerting a modest effect, epigenetic factors, which link the gene to the 
phenotype, and the environmental factors, as in the case of complex phenotypes observed in 
single‐gene disorders with Mendelian pattern of inheritance. Thus, while advances in molecu‐
lar genetics of cardiovascular diseases are gradually changing our classical understanding of 
the disease and the phenotype‐based approach to the practice of medicine, currently they are 
unlikely to be sufficient to trigger a full switch from a phenotype‐based to genotyped‐based 
medicines. A comprehensive understanding of molecular mechanism of the pathogenesis 
 integrating the genetic, epigenetic, transcriptomic, and proteomic profiles is necessary.
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